Methods of modulating ANK1

A technology of reagents and uses, applied in the field of regulation of ANK1, can solve problems that are poorly understood, etc.

Inactive Publication Date: 2019-11-19
SOC DES PROD NESTLE SA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, little is known about whether these changes in gene expression levels are causally related to obesity and weight loss, or whether they are simply a reflection of obesity status and weight loss interventions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of modulating ANK1
  • Methods of modulating ANK1
  • Methods of modulating ANK1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0226] Example 1: Association between ANK1 genetic variants and weight loss

[0227] The study involved a genetic association performed on the Diogenes weight loss intervention data and the Canadian Optifast900 study.

[0228] The Diogenes Study is a pan-European, randomized and controlled dietary intervention study that investigated the effect of dietary protein and glycemic index on weight loss and weight maintenance in obese and overweight households in eight European centers (Larsen et al. (2009) Obesity Rev. 11:76-91). Briefly, the Diogenes study included overweight / obese individuals following an 8-week low-calorie diet (LCD). LCD provides 800kcal per day by using meal replacement products (Modifast, Nutrition et Santé France).

[0229] The Canadian Optifast900 study consisted of patients enrolled in a weight management clinic who had completed a 6- to 12-week meal replacement regimen consisting of the Canadian-exclusive product Optifast900 (Nestlé Health Science, Swi...

Embodiment 2

[0233] Example 2: Prioritization of ANK1 Genetic Variants

[0234] Prioritization of GWA signals using a Bayesian framework to model the joint likelihood of associated p-values ​​with large-scale epigenome annotations. Using the RiVIERA-β framework (Li, Y. & Kellis, M. Nucleic Acids Res. 44, e144 (2016) (Li, Y. and Kellis, M., Nucleic Acids Research, Vol. 44, e144, 2016)) Such risk variance inferences were performed with 450 epigenome annotations (including histone marks, DNase I hypersensitivity, transcription factor binding, and localization within exons). The goal of the framework is to infer a posterior probability of disease for each input SNP, given its association p-value and overlap in functional annotation. Epigenomic annotations were retrieved from Pickrell et al. (Am. J. Hum. Genet. 94, 559-573 (2014) (American Journal of Human Genetics, Vol. 94, pp. 559-573, 2014)).

[0235] The benefit of such modeling is to determine which variants are likely to be the most p...

Embodiment 3

[0236] Example 3: In vivo function of ANK1

[0237] Fly races: Fly stocks were maintained on a standard diet with agar, sugar, and yeast and raised in a 25°C incubator on a 12 / 12 dark and night cycle. Actin-Gal4 from Bloomington, and w1118 and UAS-Ank IR (GD25945) from VDRC.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An agent capable of decreasing the activity of ANK1 for use in (i) reducing fat accumulation and / or (ii) preserving or increasing fat free mass is disclosed.

Description

technical field [0001] The present invention relates to agents capable of modulating the activity of ANK1 and the use of such agents in therapy, especially for (i) reducing fat accumulation and / or (ii) maintaining or increasing lean body mass in an individual. The invention also relates to methods of identifying such agents. Background technique [0002] Obesity is a chronic metabolic disease that has reached epidemic proportions in many parts of the world. Obesity is a major risk factor for serious comorbidities such as type 2 diabetes, cardiovascular disease, dyslipidemia and certain types of cancer (World Health Organ. Tech. Rep. Ser. (2000) 894: i-xii, 1- 253). [0003] Obesity refers to a condition in which an individual's body weight exceeds normal due to excessive accumulation of energy from carbohydrates, fats, and the like. Extra body weight is usually retained under the skin or around internal organs in the form of fat. [0004] Empirical data indicate that a w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113A61K31/7088
CPCA61K31/713C12N15/113C12N2310/11C12N2310/141
Inventor A·瓦尔塞西亚N·格尔多夫J·哈格尔
Owner SOC DES PROD NESTLE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap